Alaska Air Group's decision this spring to restore full Hawaiian Airlines content to the GDSs and to do away with Hawaiian's GDS surcharge is paying dividends, according to chief commercial officer ...

Coca-Cola has taken another stab at artificial-intelligence-generated holiday ads after last year’s attempts drew criticism from creative professionals over their execution and the technology’s ...

TCT 770: Clinical Outcomes of Combined RAAS Inhibitor and Statin Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement: A Large-Scale Propensity-Matched Analysis Receive the the latest ...

A global survey from the United Nations found that over 85% of people around the globe are concerned about the impact of disinformation on their fellow citizens. Recent examples abound. From viral ...

Label changes for tranexamic acid; new approval for Tezspire; psychedelic gains Breakthrough Tx status for depression; oral semaglutide approved to reduce MACE risk in T2DM; Gazyva approved for lupus ...

MUMBAI, Sept 26 (Reuters) - The BRICS countries-backed New Development Bank (NDB) plans to issue its first Indian rupee-denominated bond in the domestic market before end-March 2026, three sources ...

Primary objective: Maintain medical readiness, deliver emergency/urgent care, and support occupational health and HSE compliance in a remote, high-risk environment. I.1 Emergency response and ...

Paul Abbott, the CEO of American Express Global Business Travel, said the company hit a "key milestone" when the U.S. Department of Justice on July 29 dropped its lawsuit that sought to block the ...

I'm getting really tired of these hit pieces on supplements. I've got a chronic illness and supplements are the only thing keeping me alive. Yes, you have to be careful. No, they are not regulated by ...

A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) administered at off-label reduced dosing maintained weight-loss benefits, with patients retaining the effects even with 2-4 weeks between doses.